Rapid Micro Biosystems, Inc. · NASDAQ:RPID
Rapid Micro Biosystems — Gilmartin Group Emerging Growth Company Showcase (September 2023)
15 slides from Rapid Micro Biosystems's conference presentation, September 2023
Slide 1: Gilmartin Group Emerging Growth Company Showcase
Rapid Micro Nasdaq: RPID Gilmartin Group Emerging Growth Company Showcase , ROB SPIGNESI, PRESIDENT & CEO S SEAN WIRTJES, CFO : z_Rapidmicro (Oy biosystems SEPTEMBER 2023
Slide 2: Forward-looking statements disclaimer
This presentation has been prepared by Rapid Micro Biosystems, Inc. (the “Company”) solely for informational purposes. This presentation contains forward-looking statements. All statements that do not relate to matters of historical fact should be considered forward-looking statements, including, bu
Slide 3: Revolutionizing microbial quality control for pharmaceutical manufacturing
We are revolutionizing a critical, regulated part of the global pharmaceutical manufacturing process, bringing microbial quality control into the 21st century 3
Slide 4: Operating behind strong barriers to entry
Operating behind strong barriers to entry First mover advantage, little competition & robust patent portfolio tg An expanding $10B+ market Dominated by manual, legacy processes that face increasing FDA scrutiny Growth Direct® is the industry-leading platform Chosen by over half of the top 20 global
Slide 5: High volume testing and manual, error-prone processes
High Volume Testing and monggt by Regulators ~ ih, Subjective and Prone to Human Error pee a JN ~, “ Manual, Paper-based and | Slow > Insecure and Lacking Data Integrity
Slide 6: Introducing a revolution in MQC
Introducing a revolution in MQC SCIENTIFIC AND TECHNOLOGY INNOVATION GROWING DEMAND FOR MORE COMPLEX THERAPIES FASTER & LEANER MANUFACTURING DATA INTEGRITY & SECURITY FOCUS REGULATORY SCRUTINY DISCOVERY & RESEARCH HIGH-THROUGHPUT R&D AUTOMATION Qc & ANALYSIS BIOPROCESSING & MANUFACTURING FLEXIBLE SI
Slide 7: Growth Direct platform bringing Micro QC into the 21st Century
Growth Direct® platform bringing Micro QC into the 215* Century The only fully automated, high-throughput and secure MQC solution... Proprietary Consumables Data & Software Global Validation & Support Services THE GROWTH DIRECT® (GD) PLATFORM «delivering a compelling value proposition... Supports gl
Slide 8: Growth Direct transforms and modernizes MQC
Growth Direct® transforms and modernizes MQC 4. islets} PULL OC FILL OUT PREPARE AD TEST FORM ASSAY INFO. SAMPLES INCUBATOR MANUAL WORKTLOW 4tt PERFORM COUNTS AUTOMATED WORKFLOW 5 PERFORM RETURN COUNTS SAMPLES 14. eS Key 8 INTO LMS ce HANDLING Manual & subject to error 15 steps 5-14 days to result /
Slide 9: The Growth Direct System
The Growth Direct® System The future of microbial quality control TECHNOLOGY INNOVATION MORE COMPLEX THERAPIES SCIENTIFIC AND | GROWING DEMAND FOR FASTER & LEANER MANUFACTURING DATA INTEGRITY & SECURITY FOCUS REGULATORY SCRUTINY DISCOVERY & RESEARCH HIGH-THROUGHPUT R&D AUTOMATION Qc & ANALYSIS BIOPR
Slide 10: Automated MQC market is supported by persistent tailwinds
Automated MQC market is supported by persistent tailwinds Increasing regulatory scrutiny Growth in complex biologics, cell, and enforcement around and gene therapies which require The number of FDA warning letters due to data integrity Over 1,100 drug candidates in the findings has quadrupled cell a
Slide 11: Customer segments served
• Biologics • Small Molecules • Cell & Gene Therapy/ CAR-T • Personal Care Products • CDMO As of 6/30/2023 | Rapid Micro Biosystems 11 * By revenue
Slide 12: Innovating to enhance the Growth Direct value proposition
Innovating to enhance the Growth Direct® value proposition RMBNucleus”™ Mold Alarm Improving time to action * Utilizes proprietary vision software algorithms to provide early warning of potential mold contamination * Allows accelerated detection and contamination remediation in as little as 1 day vs
Slide 13: 2023 revenue guidance of at least 30% growth
2023 revenue guidance of ‘at least’ 30% growth lect Highlights - Q2 202 Select Highlights - Q 023 Guidance FY 2023! * Total revenue +30% y/y; recurring revenue +44% y/y ‘atleast’ $22M Total Revenue (atleast 30% growth y/y) * “Record” quarter in consumables driven by higher pull through per validated
Slide 14: Operating behind strong barriers to entry
Operating behind strong barriers to entry First mover advantage, little competition & robust patent portfolio tg An expanding $10B+ market Dominated by manual, legacy processes that face increasing FDA scrutiny Growth Direct® is the industry-leading platform Chosen by over half of the top 20 global
Slide 15: Thank You
Thank You 4 —_
Rapid Micro Biosystems — Gilmartin Group Emerging Growth Company Showcase (September 2023) on 6ix